NOVO-B.CO

Novo Nordisk A/S [NOVO-B.CO] Stock Forecast

Buy or Sell ? Support and Resistance
What is MACD and how to read it?
How RSI can help?
RSI : 000

NOVO-B.CO Stock Summary

Top 10 Correlated ETFs

NOVO-B.CO

Top 10 Correlated Stocks

NOVO-B.CO

In the News

NOVO-B.CO Financial details

Company Rating
-
Market Cap
3960.23B
Income
83.68B
Revenue
232.26B
Book val./share
-
Cash/share
-
Dividend
11.15
Dividend %
1.53%
Employees
63.37K
Optionable
No
Shortable
Yes
Earnings
02 May 2024
P/E
43.5
Forward P/E
-
PEG
36.89
P/S
15.15
P/B
35.23
P/C
-
P/FCF
41.77
Quick Ratio
0.63
Current Ratio
0.82
Debt / Equity
-
LT Debt / Equity
-
-
-
EPS (TTM)
27.4
EPS next Y
-
EPS next Q
-
EPS this Y
-23.83%
EPS next Y
-
EPS next 5Y
-
EPS last 5Y
17.92%
Revenue last 5Y
13.74%
Revenue Q/Q
12.14%
EPS Q/Q
-1.99%
-
-
-
-
SMA20
-18.45%
SMA50
-30.58%
SMA100
-44.61%
Inst Own
-
Inst Trans
-
ROA
25%
ROE
87%
ROC
0.66%
Gross Margin
84%
Oper. Margin
39%
Profit Margin
35%
Payout
42%
Shs Outstand
-
Shs Float
-
-
-
-
-
Target Price
-
52W Range
504.4-932.0
52W High
-53.32%
52W Low
-13.67%
RSI
44.4
Rel Volume
2.89
Avg Volume
2.77M
Volume
8.01M
Perf Week
3.29%
Perf Month
-17.94%
Perf Quarter
-43.41%
Perf Half Y
-43.54%
-
-
-
-
Beta
0.175
-
-
Volatility
13.42%, 49.55%
Prev Close
2.53%
Price
435.1
Change
6.54%

NOVO-B.CO Financial Performance

NOVO-B.CO Dividend History

NOVO-B.CO Frequently Asked Questions

What is Novo Nordisk A/S stock symbol ?

Novo Nordisk A/S is a DK stock and trading under the symbol NOVO-B.CO

What is Novo Nordisk A/S stock quote today ?

Novo Nordisk A/S stock price is $435.1 today.

Is Novo Nordisk A/S stock public?

Yes, Novo Nordisk A/S is a publicly traded company.

Something similar

Top by Market Cap
GOOGL
TL0.DE
CMC.DE
3V64.DE
ABEC.DE
Top Correlated ETFs
5BUS.MI
EZNC.MI
ESUG.MI
BRIC.SW
ZSB.TO
Top Correlated Stocks
1146.HK
VWS.CO
0RNP.L
2663.HK
6188.HK
Similar Market Cap
CARE.JK
8725.T
000105.KS
8002.T
8591.T

Company Profile

Healthcare Biotechnology
  • Volume Average 2.77M
  • Market Capitalization 3960.23B
  • Employee 63.37K
  • CEO Mr. Lars Fruergaard Jorgensen
  • Headquarters Bagsvaerd,DK
  • IPO Date 2001-01-06
  • Website https://www.novonordisk.com

Novo Nordisk A/S, a healthcare company, engages in the research, development, manufacture, and marketing of pharmaceutical products worldwide. It operates in two segments, Diabetes and Obesity care, and Rare Disease. The Diabetes and Obesity care segment provides products in the areas of insulins, GLP-1 and related delivery systems, oral antidiabetic products, obesity, glucagon, needles, and other chronic diseases. The Rare Disease segment offers products in the areas of haemophilia, blood disorders, endocrine disorders, growth disorders, and hormone replacement therapy. The company has a collaboration agreement with Gilead Sciences, Inc.; and research collaboration with Novo Nordisk to discover cell-specific carriers of nucleic acid therapeutics. The company was founded in 1923 and is headquartered in Bagsvaerd, Denmark.